BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27716240)

  • 1. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Verstegen NE; Maat AP; Lagerwaard FJ; Paul MA; Versteegh MI; Joosten JJ; Lastdrager W; Smit EF; Slotman BJ; Nuyttens JJ; Senan S
    Radiat Oncol; 2016 Oct; 11(1):131. PubMed ID: 27716240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy.
    Verstegen NE; Lagerwaard FJ; Hashemi SM; Dahele M; Slotman BJ; Senan S
    J Thorac Oncol; 2015 Aug; 10(8):1195-200. PubMed ID: 26200274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
    Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
    Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage surgery for local recurrences after stereotactic ablative radiotherapy of colorectal pulmonary metastases.
    van Dorp M; Ünal S; Gooijer S; Dickhoff C; van den Broek FJC; Kazemier G; Schreurs WH; Schneiders FL; Dahele M; Heineman DJ
    J Surg Oncol; 2023 Dec; 128(7):1114-1120. PubMed ID: 37477423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Dickhoff C; Dahele M; Paul MA; van de Ven PM; de Langen AJ; Senan S; Smit EF; Hartemink KJ
    Lung Cancer; 2016 Apr; 94():108-13. PubMed ID: 26973215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
    van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J
    J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA
    Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC.
    Brooks ED; Verma V; Senan S; De Baere T; Lu S; Brunelli A; Chang JY;
    J Thorac Oncol; 2020 Feb; 15(2):176-189. PubMed ID: 31712134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Enomoto T; Yokosuka T; Kaneko T; Handa H; Aoki Y; Oku Y; Kunieda E
    Ann Thorac Surg; 2013 Nov; 96(5):1776-82. PubMed ID: 23998410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.